| Objective: To investigate clinical characteristics, response, outcome, and prognosis ofperipheral blood stem cell transplantation (PBSCT) for patients with peripheral T-celllymphoma (PTCL).Methods: We retrospectively analyzed the efficaty of PBSCT in38patients withpathologically confirmed PTCL from October1994to October2010in general hospital ofPLA. Kaplan-Meier methods were applied in survival analysis and the COX regressionmodel was applied in multivariate analysis. There were ten clinical parameters appliedincluding age, sex, extranodal involvement, B symptoms, serum lactic dehydrogenase (LDH),international pronostic index (IPI), ECOG score, Ann Arbor stage, disease status pretranslant,and the type of PBSCT.Results: The patients with PTLC survived at a median of24months posttransplant. In ourstudy the2-year overall survival (OS) was46%, and the5-year OS was34%after amedianfollowup of months. The patients who received allo-PBSCT had a higherNon-relapse-mortality (NRM), but they could acieve a longer disease-free survival. Survivalanalysis with Kaplan-Meier method showed the disease status pretransplant,B symptoms,serum LDH, ECOG score,PIT score were all prognostic factors of posttransplant OS. Diseasestatus pretranslant is the only prognosic factor of allo-PBSCT.Conclusion: For refractory or relapsed PTCL patients, when conventionalchemotherapy can achieve a complete remission (CR1), the recommended regimen isautologous peripheral stem cell transplantation, if resistance to chemotherapy, althoughcan achieve remission but cannot reach CR1, suggest that regimen is allogeneicperipheral stem cell transplantation, if the conventional chemotherapy cannot reachremission, RIC-alloPBSCT will be batter. |
